A number of firms have modified their ratings and price targets on shares of Mallinckrodt PLC (NYSE: MNK) recently:

  • 11/8/2017 – Mallinckrodt PLC was downgraded by analysts at Wells Fargo & Company from an “outperform” rating to a “market perform” rating.
  • 11/8/2017 – Mallinckrodt PLC was downgraded by analysts at Barclays PLC from an “overweight” rating to an “equal weight” rating. They now have a $23.00 price target on the stock, down previously from $65.00.
  • 11/8/2017 – Mallinckrodt PLC is now covered by analysts at Jefferies Group LLC. They set a “buy” rating and a $30.00 price target on the stock.
  • 11/8/2017 – Mallinckrodt PLC was downgraded by analysts at Goldman Sachs Group, Inc. (The) from a “buy” rating to a “neutral” rating. They now have a $55.00 price target on the stock.
  • 11/8/2017 – Mallinckrodt PLC had its price target lowered by analysts at BMO Capital Markets to $38.00. They now have an “outperform” rating on the stock.
  • 11/8/2017 – Mallinckrodt PLC had its price target lowered by analysts at Morgan Stanley from $40.00 to $27.00. They now have an “equal weight” rating on the stock.
  • 11/8/2017 – Mallinckrodt PLC had its price target lowered by analysts at Stifel Nicolaus from $70.00 to $50.00. They now have a “buy” rating on the stock.
  • 11/8/2017 – Mallinckrodt PLC had its price target lowered by analysts at Canaccord Genuity from $38.00 to $24.00. They now have a “buy” rating on the stock.
  • 11/7/2017 – Mallinckrodt PLC was downgraded by analysts at Deutsche Bank AG from a “buy” rating to a “hold” rating. They now have a $28.00 price target on the stock, down previously from $44.00.
  • 11/7/2017 – Mallinckrodt PLC was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “hold” rating. They now have a $28.00 price target on the stock, down previously from $44.00.
  • 11/6/2017 – Mallinckrodt PLC was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Mallinckrodt is focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures to transform the portfolio. The company sold its Nuclear Imaging business and Intrathecal Therapy business. Acthar sales continue to be strong on the back of increased formulary positions and access for appropriate patients in both the commercial and public environments and we expect Acthar sales to drive growth. However, sales of Therakos is expected to decline. The company's generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. The company expects double-digit declines in revenues from this segment. Shares of the company have underperformed the industry so far in 2017. A U.S. District Court recently invalidated 11 patents covering its second-largest product Inomax.”
  • 11/2/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $52.00 price target on the stock.
  • 10/31/2017 – Mallinckrodt PLC was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Mallinckrodt is focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures to transform the portfolio. The company sold its Nuclear Imaging business and Intrathecal Therapy business. While Acthar sales continue to be strong on the back of increased formulary positions and access for appropriate patients in both the commercial and public environments, sales of Therakos is expected to decline. The company's generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. The company expects double-digit declines in revenues from this segment. Shares of the company have underperformed the industry so far in 2017. A U.S. District Court recently invalidated 11 patents covering its second-largest product Inomax.”
  • 10/25/2017 – Mallinckrodt PLC was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures to transform the portfolio and become a high-performing specialty pharmaceutical company. The company sold its Nuclear Imaging business and Intrathecal Therapy business to focus on its key areas. While Acthar sales continue to be strong on the back of increased formulary positions and access for appropriate patients in both the commercial and public environments, sales of Therakos is expected to decline. The generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. The company expects double-digit declines in revenues from this segment. Shares of the company have underperformed the industry so far in 2017.”
  • 10/21/2017 – Mallinckrodt PLC was given a new $67.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 10/17/2017 – Mallinckrodt PLC was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures to transform the portfolio and become a high-performing specialty pharmaceutical company. The company sold its Nuclear Imaging business and Intrathecal Therapy business to focus on its key areas. While Acthar sales continue to be strong on the back of increased formulary positions and access for appropriate patients in both the commercial and public environments, sales of Therakos is expected to decline. The generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. The company expects double-digit declines in revenues from this segment. Shares of the company have underperformed the industry so far in 2017.”
  • 10/15/2017 – Mallinckrodt PLC had its “hold” rating reaffirmed by analysts at Mizuho. They now have a $40.00 price target on the stock.
  • 10/6/2017 – Mallinckrodt PLC was given a new $70.00 price target on by analysts at UBS AG. They now have a “buy” rating on the stock.
  • 10/6/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $60.00 price target on the stock.
  • 10/6/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at Stifel Nicolaus.
  • 10/5/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $67.00 price target on the stock.
  • 10/4/2017 – Mallinckrodt PLC was downgraded by analysts at Canaccord Genuity from a “buy” rating to a “hold” rating. They now have a $40.00 price target on the stock, down previously from $77.00.
  • 10/2/2017 – Mallinckrodt PLC was given a new $52.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 10/2/2017 – Mallinckrodt PLC was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 9/28/2017 – Mallinckrodt PLC is now covered by analysts at Goldman Sachs Group, Inc. (The). They set a “buy” rating and a $55.00 price target on the stock.
  • 9/19/2017 – Mallinckrodt PLC had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $70.00 to $48.00.
  • 9/15/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $67.00 price target on the stock.
  • 9/14/2017 – Mallinckrodt PLC had its price target lowered by analysts at Citigroup Inc. to $45.00. They now have a “buy” rating on the stock.
  • 9/14/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $45.00 price target on the stock, down previously from $56.00.

Mallinckrodt PLC (NYSE:MNK) opened at $21.76 on Monday. The stock has a market cap of $2,067.31, a price-to-earnings ratio of 2.94, a P/E/G ratio of 0.32 and a beta of 1.46. Mallinckrodt PLC has a 1 year low of $19.00 and a 1 year high of $68.12. The company has a current ratio of 1.38, a quick ratio of 0.81 and a debt-to-equity ratio of 1.08.

Mallinckrodt PLC (NYSE:MNK) last released its quarterly earnings data on Tuesday, November 7th. The company reported $1.97 earnings per share for the quarter, beating analysts’ consensus estimates of $1.80 by $0.17. Mallinckrodt PLC had a net margin of 11.43% and a return on equity of 14.79%. The company had revenue of $793.90 million during the quarter, compared to analysts’ expectations of $808.93 million. During the same quarter in the previous year, the company earned $2.04 earnings per share. The firm’s revenue for the quarter was down 10.5% on a year-over-year basis. equities analysts anticipate that Mallinckrodt PLC will post 7.23 EPS for the current fiscal year.

In other news, insider Meredith B. Fischer acquired 1,280 shares of the business’s stock in a transaction on Wednesday, August 30th. The stock was bought at an average price of $39.63 per share, with a total value of $50,726.40. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.77% of the stock is currently owned by insiders.

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.

Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.